Vorozole
From Wikipedia, the free encyclopedia
|
Vorozole
|
|
| Systematic (IUPAC) name | |
| 6-[(4-chlorophenyl)-(1,2,4-triazol-1-yl)methyl]- 1-methyl-benzotriazole |
|
| Identifiers | |
| CAS number | |
| ATC code | L02 |
| PubChem | |
| Chemical data | |
| Formula | C16H13ClN6 |
| Mol. mass | 324.768 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Very high |
| Metabolism | Hepatic |
| Half life | 8 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Vorozole is an imidazole based competative inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.

